THE REPORTER TO

torney Docket No. Le A 33 878

e application of: Alonso-Alija. et al.

Group No.:

Serial No.: 10/088,060

Examiner:

Filed: 03/13/2002

For: "Novel Derivatives of Dicarboxylic Acid Having Pharmaceutical Properties"

CERTIFICATION OF MAILING UNDER 37 C.F.R. 1.8(a)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

I hereby certify that this correspondence and any papers referred to as attached are being deposited, on the date shown below, with the United States Postal Service, with sufficient postage, as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Date: AUG 1 3 2002

Ms. Mariellen Chapdulaure Signature of Person Certifying

ASSISTANT COMMISSIONER FOR PATENTS WASHINGTON, D.C. 20231

TRANSMITTAL OF SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BEFORE MAILING OF FIRST OFFICE ACTION (37 C.F.R. 1.97(b))

Dear Sir:

Applicants wish to cite for the record in the above-identified application the references shown on the accompanying copy of PTO form 1449.

IDENTIFICATION OF TIME OF FILING THE ACCOMPANYING INFORMATION DISCLOSURE STATEMENT

The information disclosure statement transmitted herewith is being filed **before** the mailing date of the first Office action on the merits.

FEE PAYMENT

Applicants believe that no fees are due with this submission. However, the Commissioner is hereby authorized to charge any fees that may have been overlooked but that are required to Deposit Account 13-3372. Additionally, please credit any overpayment to the same account.

Respectfully submitted,

Reg. No. 31,018

Telephone: (203) 812-2712

Date:

12 any '12

William F. Gray Attorney for Applicant(s) Bayer Corporation 400 Morgan Lane

West Haven, CT 06516

Mm PNO-1449C (Modified)

U.S. Department of Commerce Patent and Trademark Office Serial No. 10/088,060

Group Art Unit

Filing Date 03/13/2002

Atty. Docker No Le A 33 878

5 2 ^{Q 2002} SUPPLEMENTAL INFORMATION DISCLOSURE CITATION

Applicant(s) Alonso-Alija, et al.

U.S. PATENT DOCUMENTS


*	DOCUMENT NO.	DATE MM/DD/YY	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE

					FO	REIG	N PA	TENT DOCU	JMENTS				
	DOCUMENT NO.							DATE COUNTRY	COUNTRY	PRIMARY	SUB-	TRANSLATION	
								DD/MM/YY		CLASS	CLASS	YES	NO
F3	0	3	4	5	0	6	8	06/12/89	EP				
F4	9	3	0	0	3	5	9	07/01/93	WO				
F5	9	8	1	6	2	2	3	23/04/98	wo				
F6	9	8	1	6	5	0,	7	23/04/98	wo				
F7	9	8	2	3	6	1	9	04/06/98	wo				
F8	o	3	4	1	5	5	1	15/11/89	ЕР				

	OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)								
R1	Ko, F., Wu, C., Kuo, S., Lee, F., Teng, C., "YC-1, A Novel Activator of Platelet Guanylate Cyclase", Blood 84: 4226-4233 (1994)								
R2	Mulsch, A., Bauersachs, J., Schafer, A., Stasch, J., Kast, R., Busse, R., "Effect of YC-1, An NO-Independent, Superoxide-Sensitive Stimulator of Soluble Guanylyl Cyclase, On Smooth Muscle Responsiveness to Nitrovasodilators", Br. J. Pharmacol., 120: 681-689 (1997)								
R3	Glass, D., Frey, W., Carr, D., Goldberg, N., "Stimulation of Human Platelet Guanylate Cyclase by Fatty Acids", J. Biol. Chem., <u>252</u> : 1279-1285 (1977)								
R4	Pettibone, D., Sweet, C., Risley, E., Kennedy, T., "A Structurally Novel Stimulator of Guanylate Cyclase With Long-Lasting Hypotensive Activity in the Dog", Eur. J. Pharmacol., <u>116</u> : 307-312 (1985)								
R5	Yu, S., Kuo, S., "Vasorelaxant Effect of Isoliquiritigenin, A Novel Soluble Guanylate Cyclase Activator, In Rat Aorta", Br. J. Pharmacol., 114: 1587-1594 (1995)								
R6	Gerzer, R., Bohme, E., Hofmann, F., Schultz, G., "Soluble Guanylate Cyclase Purified From Bovine Lung Contains Heme and Copper", FEBS Lett., 132: 71-74 (1981)								
R7	Hoenicka, M., Becker, E., Apeler, H., Sirichoke, T., Schroder, H., Gerzer, R., Stasch, J., "Purified Soluble Guanylyl Cyclase Expressed in a Baculovirus/Sf9 System: Stimulation by YC-1, Nitric Oxide, and Carbon								

DATE CONSIDERED

^{*} EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.